In a flurry of activity, multiple biopharma companies made their first appearance on the Nasdaq Stock Exchange on June 25, raising hundreds of millions of dollars to advance the development of next-generation therapeutics and scale their businesses.

Seattle-based clinical-stage biopharmaceutical company Lumen Bioscience is teaming up with Novo Nordisk to explore research and development opportunities within obesity, among other metabolic disorders.

UnitedHealthcare announced a community-based initiative, Community Catalyst, that convenes a broad range of community stakeholders to identify and address specific health care needs of members of the community and residents of publicly assisted housing who are often difficult to reach and serve.

Xilio Therapeutics is evaluating the company’s tumor-selective anti-CTLA-4 antibody XTX101 with Merck’s programmed death receptor-1 therapy Keytruda (pembrolizumab). The clinical trial – which will be conducted by Xilio – will assess XTX101’s safety and efficacy as a monotherapy, as well as in combination with Keytruda, in solid tumors.

GlaxoSmithKline’s entire stake in Innoviva was sold back to the U.S.-based biopharmaceutical company for about $392 million, the British drugmaker said on May 20, as GSK simplifies operations ahead of a split into two businesses.

Vir Biotechnology, Eli Lilly and GlaxoSmithKline struck a three-way collaborative deal to evaluate Vir’s investigational monoclonal antibody VIR-7831 in combination with Lilly’s bamlanivimab in low-risk patients with mild to moderate Covid-19.

UCB S.A. is flexing the company’s M&A muscles once again with the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company based in Leuven, Belgium.

GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a Covid-19 vaccine candidate under development by the two companies.

French drugmaker Sanofi SA expects to get approval for the potential COVID-19 vaccine in development with Britain’s GlaxoSmithKline Plc by the first half of 2021, faster than previously anticipated.

MADRID (Reuters) – The leaders of six European Union nations have called for building up EU stocks of critical medicines and equipment and other measures to boost the bloc’s long-term resilience to public health crises. The 27-nation EU and Britain have reported some 1.4 million cases of the new coronavirus, or about a fifth of […]